Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Sanofi crawled date : 2021 - 03 - 31 save search
FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Published: 2021-03-31 (Crawled : 23:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
fda fda approval
Correlation Ventures Announces 300th Investment and Three Key Hires
Published: 2021-03-31 (Crawled : 23:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
correlation
Achieve organizational flexibility, so you can focus your attention on strategy
Published: 2021-03-31 (Crawled : 23:00) - modeln.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Published: 2021-03-31 (Crawled : 22:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
fda fda approval
Worldwide Chronic Kidney Disease Drugs Industry to 2029 - High prevalence of Chronic Kidney Disease is Driving Growth
Published: 2021-03-31 (Crawled : 20:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.19%
H: 0.41%
C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -1.06%
H: 0.76%
C: 0.14%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.48%
C: 0.2%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: 0.37%
H: 0.49%
C: -1.11%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.22%
H: 0.35%
C: -0.16%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.37%
H: 0.11%
C: -0.22%
disease drug growth kidney
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
Published: 2021-03-31 (Crawled : 14:15) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.59%
H: 0.36%
C: 0.12%
vaccine influenza
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
Published: 2021-03-31 (Crawled : 11:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.11%
H: 0.77%
C: 0.22%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.59%
H: 0.36%
C: 0.12%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 4.81%
H: 1.4%
C: -0.25%
covid positive results topline vaccine covid-19
Insights on the Global Vaccines Market 2021-2025: Industry Analysis, Market Drivers, Market Challenges, Opportunities and Forecast 2025 - Technavio
Published: 2021-03-31 (Crawled : 03:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.59%
H: 0.36%
C: 0.12%
vaccine market
NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients
Published: 2021-03-30 (Crawled : 00:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.59%
H: 0.36%
C: 0.12%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.42%
H: 0.65%
C: 0.11%
injection trial diabetic diabetes
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.